Short Interest in PainReform Ltd. (NASDAQ:PRFX) Increases By 232.9%

PainReform Ltd. (NASDAQ:PRFX) saw a significant growth in short interest in the month of April. As of April 15th, there was short interest totalling 54,600 shares, a growth of 232.9% from the March 31st total of 16,400 shares. Currently, 3.0% of the shares of the stock are short sold. Based on an average daily trading volume, of 135,900 shares, the days-to-cover ratio is presently 0.4 days.

Institutional Trading of PainReform

A hedge fund recently bought a new stake in PainReform stock. Armistice Capital LLC purchased a new stake in PainReform Ltd. (NASDAQ:PRFX) during the 4th quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor purchased 170,000 shares of the company’s stock, valued at approximately $468,000. Armistice Capital LLC owned approximately 10.90% of PainReform at the end of the most recent reporting period. Institutional investors and hedge funds own 37.28% of the company’s stock.

PainReform Stock Down 2.1 %

Shares of NASDAQ PRFX opened at $0.84 on Friday. PainReform has a 12-month low of $0.69 and a 12-month high of $26.41. The firm’s 50-day moving average is $1.69 and its two-hundred day moving average is $2.14.

About PainReform

PainReform Ltd., a clinical stage specialty pharmaceutical company, focuses on the reformulation of established therapeutics and provides an extended period of post-surgical pain relief in Israel. It develops PRF-110, a viscous clear oil-based solution that is instilled directly into the surgical wound to provide localized and extended post-operative analgesia, as well as in Phase 3 clinical trial for pain treatment of patients undergoing bunionectomy and second trial for pain treatment of hernia repair operations.